913e CLINICAL VALIDATION OF A CELL-FREE DNA BLOOD-BASED TEST FOR COLORECTAL CANCER SCREENING IN AN AVERAGE RISK POPULATION
Daniel C. Chung(Massachusetts General Hospital), William M. Grady(Seattle University), Harminder Singh(CancerCare Manitoba), Darrell M. Gray(CancerCare Manitoba), Frank A. Sinicrope(Mayo Clinic in Arizona), Samir Gupta(University of California San Diego), Joel K. Greenson(University of Michigan), Sylvia Hu(Guardant (United States)), Rachel B. Issaka(University of Washington), Craig Eagle(Pfizer (United States)), AmirAli Talasaz(Guardant (United States))
Cited by 7
Related Papers
Fusobacterium nucleatum Potentiates Intestinal Tumorigenesis and Modulates the Tumor-Immune Microenvironment
|Cell Host & Microbe|2013|2.7k
Direct evidence that the VEGF-specific antibody bevacizumab has antivascular effects in human rectal cancer
|Nature Medicine|2004|2k
Gastroenteropancreatic neuroendocrine tumours
|The Lancet Oncology|2008|1.8k
Celecoxib for the Prevention of Sporadic Colorectal Adenomas
|New England Journal of Medicine|2006|1k
Genomic and Epigenetic Instability in Colorectal Cancer Pathogenesis
|Gastroenterology|2008|942